Jason Ayres, MD
Family Medicine · Southside, ALNPI 1972566776
Payments from drug & device makers
Across 190 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$374
- AbbVie$349
- Pfizer$301
- Novo Nordisk$273
- Boehringer Ingelheim$267
- Amgen$215
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,966100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $374 |
| AbbVie(2 entities) | 23 | $349 |
| Pfizer | 23 | $301 |
| Novo Nordisk | 16 | $273 |
| Boehringer Ingelheim | 19 | $267 |
| Amgen | 15 | $215 |
| GSK | 10 | $168 |
| Bayer | 8 | $158 |
| Lilly USA, LLC | 9 | $137 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Novartis | 5 | $70 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Dexcom, Inc. | 3 | $53 |
| Merck | 4 | $48 |
| Johnson & Johnson | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Medtronic | 2 | $41 |
| Lundbeck LLC | 2 | $35 |
| Exact Sciences | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Corcept Therapeutics | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$2,966 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 257 | $259,160 |
| EliquisApixaban | 196 | $150,258 |
| FarxigaDapagliflozin Propanediol | 175 | $121,776 |
| JardianceEmpagliflozin | 91 | $86,142 |
| MounjaroTirzepatide | 72 | $83,345 |
| XareltoRivaroxaban | 66 | $65,487 |
| Abilify MaintenaAripiprazole | 14 | $37,018 |
| Xigduo XrDapaglifloz Propaned/Metformin | 43 | $36,219 |
| OxycontinOxycodone Hcl | 21 | $33,878 |
| TrulicityDulaglutide | 28 | $31,796 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $26,006 |
| JanuviaSitagliptin Phosphate | 31 | $22,577 |
| MyrbetriqMirabegron | 40 | $21,058 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $20,672 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $17,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $273 | $259,160257 claims |
| PfizerEliquis | $301 | $150,258196 claims |
| AstraZenecaFarxiga | $374 | $121,776175 claims |
| Lilly USA, LLCMounjaro, Trulicity | $137 | $115,142100 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $267 | $92,645102 claims |
| Johnson & JohnsonXarelto, Invokamet | $44 | $72,47478 claims |
| MerckJanuvia, Janumet, Janumet Xr | $48 | $60,32990 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix | $168 | $44,854119 claims |
| AbbVieLinzess | $349 | $8,48516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Southside
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.